LEXINGTON, Mass., Aug. 1, 2017 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage
biotechnology company devoted to treating inflammation, inborn
errors of metabolism, and other diseases related to aldehydes,
today announced it will issue financial results for the second
quarter ended June 30, 2017, on
Tuesday, August 8, 2017, prior to the
market open.
Aldeyra will hold a conference call on Tuesday, August 8, 2017, at 8:00 a.m. EDT to discuss the results. The
dial-in numbers are 1-877-870-4263 for domestic callers and
1-412-317-0790 for international callers. A live webcast of
the conference call will also be available on the investor
relations page of the Aldeyra Therapeutics corporate website
at www.aldeyra.com.
After the live webcast, the event will remain archived on the
Aldeyra Therapeutics website for one year.
About Aldeyra
Therapeutics
Aldeyra Therapeutics, Inc. is a
biotechnology company devoted to improving lives by inventing,
developing and commercializing products that treat diseases thought
to be related to endogenous aldehydes, a naturally occurring class
of pro-inflammatory and toxic molecules. Aldeyra's lead product
candidate, ADX-102, is an aldehyde trap in development for ocular
inflammation, as well as for Sjögren-Larsson Syndrome and Succinic
Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of
aldehyde metabolism. Aldeyra's product candidates have not been
approved for sale in the U.S. or elsewhere.
Corporate Contact:
Stephen Tulipano
Aldeyra Therapeutics, Inc.
Tel: +1 781-761-4904 ext. 205
stulipano@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com
Media Contact:
Cammy Duong
MacDougall Biomedical Communications
781-591-3443
cduong@macbiocom.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-second-quarter-2017-financial-results-300497215.html
SOURCE Aldeyra Therapeutics, Inc.